Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Sareum's clinical trial applications (CTAs) for CHK1 inhibitor drug candidate CCT245737.
Subscribe to our email newsletter
Sareum plans to start clinical trials in second quarter of this year, subject to final NHS approval.
The company plans to carry out two phase I clinical trials in cancer patients in partnership with co-development partners, the CRT Pioneer Fund.
In one trial, CCT245737 will be used in combination with standard-of-care chemotherapy, targeting lung and pancreatic cancer patients.
The other trial will utilize CCT245737 as a single anti-cancer agent and will initially target several cancers.
Sareum CEO Tim Mitchell said: "This approval for CCT245737 is another significant milestone along its path to being the first from our development pipeline to enter clinical trials."
Studies have demonstrated that oral dosing of CCT245737 and other lead series compounds can boost the activity of relevant chemotherapies in in vivo models of lung, pancreatic and colon cancers.
The inhibitors also exhibited strong efficacy when dosed as a single anti-cancer agent in various in vivo models, including those of acute myeloid leukaemia lymphoma and paediatric neuroblastoma.
Sareum is engaged in the discovery and development of drug candidates intended at cancers and autoimmune diseases.
The company’s drug development programs intend to enhance outcomes for patients with severe medical conditions and where existing therapies are inadequate.